NFKB1 and B-cell chronic lymphocytic leukemia: Because we previously showed that ATO downregulates NF-κB and activates c-Jun N-terminal kinase (JNK) in CLL cells [9], we studied whether ATO regulated the JNK downstream effectors c-fos and c-jun, two components of the AP-1 heterodimer.